Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spiramycin: safety in man.

J Descotes1, T Vial, D Delattre

  • 1Laboratoire de Pharmacologie, Unité INSERM U80-CNRS UA1177-UCBL Faculté de Médecine Alexis Carrel, Lyon, France.

The Journal of Antimicrobial Chemotherapy
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tritiated thymidine incorporation does not enhance sensitivity of the popliteal lymph node assay.

Toxicology·2003
Same author

[Deleterious cardiac effects of serotonin in myocardial ischemia: role of naftidrofuryl].

Annales de cardiologie et d'angeiologie·2003
Same author

[Anaphylactic shock associated with ceftriaxone therapy in a newborn].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2002
Same author

[Cardiotoxicity of 5-fluorouracil: report of 6 cases].

Therapie·2002
Same author

Effect of murine recombinant IL-2 on the course of lupus-like disease in (NZBxNZW) F1 female mice.

Immunopharmacology and immunotoxicology·2002
Same author

[OPPIDUM, a tool for assessing the local misuse of psychotropic drugs?].

Therapie·2002
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Spiramycin, a macrolide antibiotic, shows a favorable safety profile with minimal gastrointestinal and allergic side effects. Unlike other macrolides, it demonstrates a lack of significant drug interactions and no conclusive evidence of liver injury.

Area of Science:

  • Pharmacology
  • Clinical Toxicology
  • Microbiology

Background:

  • Spiramycin is a 16-membered macrolide antibiotic with a 15-year clinical history.
  • Macrolide antibiotics, including erythromycin, can cause gastrointestinal disturbances and drug interactions.
  • Hepatotoxicity is a potential concern with various macrolide treatments.

Purpose of the Study:

  • To evaluate the safety and tolerability of spiramycin in clinical use.
  • To compare the adverse effect profile of spiramycin with other macrolides.
  • To investigate the potential for drug interactions and hepatotoxicity associated with spiramycin.

Main Methods:

  • Review of clinical data and adverse event reports for spiramycin.
  • Experimental studies on gastrointestinal motility.

Related Experiment Videos

  • Biochemical and pharmacokinetic analyses to assess drug interactions.
  • Clinical studies to confirm drug interaction profiles.

    • Main Results:

    • Spiramycin exhibits minimal serious toxicity over 15 years of clinical use.
    • Gastrointestinal disturbances are typically mild and do not affect motility, unlike erythromycin.
    • Allergic reactions are uncommon, primarily transient skin eruptions.
    • No conclusive evidence of spiramycin-induced hepatitis exists.
    • Spiramycin has a well-established lack of drug interactions.

    Conclusions:

    • Spiramycin is a well-tolerated macrolide antibiotic with a low incidence of adverse effects.
    • Its safety profile is distinguished by minimal gastrointestinal impact, rare allergic reactions, absence of significant drug interactions, and no confirmed hepatotoxicity.
    • Spiramycin represents a safer alternative within the macrolide class, particularly for patients at risk of drug interactions or gastrointestinal upset.